Allan joined Sygnature Discovery in February 2019 and serves as Vice President of Oncology Drug Discovery.<\/p>\n\n\n\n
With more than 25 years of experience in medicinal chemistry and drug discovery, Allan has an outstanding track record of advancing compounds into clinical trials across multiple therapeutic areas. Before joining Sygnature, he spent nine years as Head of Chemistry at the Cancer Research UK Manchester Institute Drug Discovery Unit.<\/p>\n\n\n\n
During his time at CRUK, Allan led internal research programs as well as national and international collaborations to deliver innovative oncology therapeutics. His responsibilities spanned synthetic and medicinal chemistry, computational chemistry, informatics, and structural biology. Beyond his scientific leadership, Allan remains deeply committed to science communication and public engagement\u2014personally interacting with more than 20,000 CRUK supporters through events and media appearances during his time with the charity. In recognition of these efforts, he received CRUK\u2019s prestigious \u201cFlame of Hope\u201d award<\/strong> in 2016, the charity\u2019s highest honor for voluntary service. He remains a frequent speaker at global drug discovery conferences.<\/p>\n\n\n\n Allan holds a BSc (Hons) in Chemistry and a PhD in Synthetic Organic Chemistry from UMIST\/the University of Manchester, followed by postdoctoral research at the University of Reading.<\/p>\n\n\n\n Want to connect with Allan?<\/strong>
Check out our Events page to see where he\u2019ll be speaking next at one of our events<\/a> and feel free to reach out to him on LinkedIn<\/a> before the event.<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":9149,"template":"","team_group":[667],"class_list":["post-1412","people","type-people","status-publish","has-post-thumbnail","hentry","team_group-research-management-team"],"acf":[],"yoast_head":"\n